SI3845221T1 - Trdne oblike sofosbuvirja - Google Patents
Trdne oblike sofosbuvirjaInfo
- Publication number
- SI3845221T1 SI3845221T1 SI201531985T SI201531985T SI3845221T1 SI 3845221 T1 SI3845221 T1 SI 3845221T1 SI 201531985 T SI201531985 T SI 201531985T SI 201531985 T SI201531985 T SI 201531985T SI 3845221 T1 SI3845221 T1 SI 3845221T1
- Authority
- SI
- Slovenia
- Prior art keywords
- sofosbuvir
- solid state
- state forms
- forms
- solid
- Prior art date
Links
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 title 1
- 229960002063 sofosbuvir Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1610DE2014 | 2014-06-13 | ||
| EP14002279 | 2014-07-03 | ||
| EP14180278 | 2014-08-07 | ||
| IN2268DE2014 | 2014-08-08 | ||
| US201562119599P | 2015-02-23 | 2015-02-23 | |
| US201562157043P | 2015-05-05 | 2015-05-05 | |
| EP15167228 | 2015-05-11 | ||
| EP15167683 | 2015-05-13 | ||
| IN1348DE2015 | 2015-05-14 | ||
| EP15169888 | 2015-05-29 | ||
| EP20212270.1A EP3845221B1 (en) | 2014-06-13 | 2015-06-12 | Solid state forms of sofosbuvir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3845221T1 true SI3845221T1 (sl) | 2024-03-29 |
Family
ID=54832933
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530663T SI3154526T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvira |
| SI201531513T SI3524234T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvira |
| SI201531985T SI3845221T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvirja |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530663T SI3154526T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvira |
| SI201531513T SI3524234T1 (sl) | 2014-06-13 | 2015-06-12 | Trdne oblike sofosbuvira |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10214553B2 (sl) |
| EP (3) | EP3845221B1 (sl) |
| CA (1) | CA2988393C (sl) |
| ES (1) | ES2971478T3 (sl) |
| SI (3) | SI3154526T1 (sl) |
| WO (2) | WO2015191945A2 (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2015443A3 (cs) * | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Farmaceutická formulace sofosbuviru |
| CN107710050A (zh) | 2015-06-30 | 2018-02-16 | 3M创新有限公司 | 照明器 |
| EP3430023A1 (en) | 2016-03-17 | 2019-01-23 | Mylan Laboratories, Limited | Polymorphic forms of sofosbuvir |
| CN106220639A (zh) * | 2016-07-22 | 2016-12-14 | 上海众强药业有限公司 | 一种维帕他韦中间体新晶型 |
| CZ2016553A3 (cs) * | 2016-09-09 | 2018-03-21 | Zentiva, K.S. | Pevná farmaceutická dávková forma obsahující sofosbuvir |
| CN106432253B (zh) * | 2016-09-21 | 2019-06-14 | 上海众强药业有限公司 | 一种维帕他韦新晶型及其制备方法 |
| RU2656228C9 (ru) * | 2017-06-13 | 2019-04-16 | Олег Ростиславович Михайлов | Слабозакристаллизованная β-модификация (S)-изопропил 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)-(фенокси)фосфориламино)пропаноата, способ её получения и фармацевтическая композиция на её основе |
| WO2019025600A1 (en) | 2017-08-03 | 2019-02-07 | Sandoz Ag | SOFOSBUVIR HYDRATE |
| CN110693887B (zh) * | 2019-05-17 | 2022-06-17 | 歌礼药业（浙江）有限公司 | 包含索磷布韦和拉维达韦的片剂及其制备方法 |
| CN111773192B (zh) * | 2020-08-18 | 2024-08-02 | 福建广生堂药业股份有限公司 | 一种索磷布韦片剂及其制备方法 |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| ES2437933T3 (es) * | 2010-01-28 | 2014-01-15 | F. Hoffmann-La Roche Ag | 4'-azido-nucleósidos como compuestos anti-VHC |
| JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
| TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
| AU2012346217B2 (en) * | 2011-11-29 | 2016-02-04 | Gilead Sciences, Inc. | Compositions and methods for treating hepatitis C virus |
| US8889159B2 (en) * | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| KR20150027155A (ko) | 2012-07-03 | 2015-03-11 | 브리스톨-마이어스 스큅 컴퍼니 | 바이러스 감염의 치료를 위한 뉴클레오시드 화합물의 부분입체이성질체적으로 풍부한 포스포르아미데이트 유도체의 제조 방법 |
| KR20200060782A (ko) | 2013-01-31 | 2020-06-01 | 길리애드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| US10100075B2 (en) | 2013-12-23 | 2018-10-16 | Mylan Laboratories Limited | Process for the preparation of sofosbuvir |
| TW201609785A (zh) | 2013-12-23 | 2016-03-16 | 吉李德製藥公司 | 固體型之抗病毒化合物 |
| WO2015126995A1 (en) * | 2014-02-20 | 2015-08-27 | Ratiopharm Gmbh | Solid state forms of sofosbuvir |
| US20170080008A1 (en) | 2014-03-05 | 2017-03-23 | Galenicum Health S.L. | Stable pharmaceutical compositions of sofosbuvir |
| CN106163529A (zh) | 2014-04-03 | 2016-11-23 | 桑多斯股份公司 | 包含无定形索非布韦的固体组合物 |
| CZ2014502A3 (cs) | 2014-07-17 | 2016-01-27 | Zentiva, K.S. | Nová forma sofosbuviru a způsob její přípravy |
| JP2017522343A (ja) | 2014-07-31 | 2017-08-10 | サンド・アクチエンゲゼルシヤフト | ホスホルアミデート類の合成 |
| TW201609709A (zh) | 2014-08-01 | 2016-03-16 | Ｈｃ製藥公司 | 呈晶形之索非布弗（Ｓｏｆｏｓｂｕｖｉｒ）及其製備方法 |
| CN104130302B (zh) | 2014-08-08 | 2017-02-15 | 乳源东阳光药业有限公司 | 一种核苷药物的晶型及其制备方法 |
| WO2016023906A1 (en) | 2014-08-13 | 2016-02-18 | Sandoz Ag | A crystalline form of sofosbuvir |
| WO2016023905A1 (en) | 2014-08-13 | 2016-02-18 | Sandoz Ag | New and efficient process for the preparation of crystalline form 6 of sofosbuvir |
| WO2016035006A1 (en) | 2014-09-01 | 2016-03-10 | Dr. Reddy’S Laboratories Limited | Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir |
| WO2016038542A2 (en) | 2014-09-10 | 2016-03-17 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
| WO2016055576A1 (en) | 2014-10-08 | 2016-04-14 | Sandoz Ag | High drug load tablets comprising sofosbuvir |
| CN104277088A (zh) | 2014-10-29 | 2015-01-14 | 汤律进 | 索菲布韦单晶m及其制备方法和用途 |
| CN106046088B (zh) | 2014-11-07 | 2018-05-15 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型h3及其制备方法 |
| WO2016097173A1 (en) | 2014-12-17 | 2016-06-23 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
| WO2016156512A1 (en) | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
| WO2016189443A2 (en) | 2015-05-23 | 2016-12-01 | Virupaksha Organics Limited | Solid forms of nucleoside phosphoramidate |
| EP3430023A1 (en) | 2016-03-17 | 2019-01-23 | Mylan Laboratories, Limited | Polymorphic forms of sofosbuvir |
-
2015
- 2015-06-12 US US15/318,385 patent/US10214553B2/en active Active
- 2015-06-12 CA CA2988393A patent/CA2988393C/en active Active
- 2015-06-12 EP EP20212270.1A patent/EP3845221B1/en active Active
- 2015-06-12 SI SI201530663T patent/SI3154526T1/sl unknown
- 2015-06-12 WO PCT/US2015/035457 patent/WO2015191945A2/en not_active Ceased
- 2015-06-12 ES ES20212270T patent/ES2971478T3/es active Active
- 2015-06-12 SI SI201531513T patent/SI3524234T1/sl unknown
- 2015-06-12 EP EP19154561.5A patent/EP3524234B1/en active Active
- 2015-06-12 SI SI201531985T patent/SI3845221T1/sl unknown
- 2015-06-12 WO PCT/EP2015/063163 patent/WO2015189386A1/en not_active Ceased
- 2015-06-12 EP EP15733573.8A patent/EP3154526B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3524234B1 (en) | 2020-12-09 |
| EP3845221A1 (en) | 2021-07-07 |
| EP3154526B1 (en) | 2019-03-06 |
| CA2988393C (en) | 2023-08-22 |
| WO2015189386A1 (en) | 2015-12-17 |
| SI3524234T1 (sl) | 2021-05-31 |
| EP3154526A2 (en) | 2017-04-19 |
| EP3845221B1 (en) | 2023-12-13 |
| SI3154526T1 (sl) | 2019-08-30 |
| ES2971478T3 (es) | 2024-06-05 |
| US10214553B2 (en) | 2019-02-26 |
| WO2015191945A2 (en) | 2015-12-17 |
| CA2988393A1 (en) | 2015-12-17 |
| WO2015191945A3 (en) | 2016-04-07 |
| EP3524234A1 (en) | 2019-08-14 |
| US20170137453A1 (en) | 2017-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250511A0 (en) | Crystalline forms of ibrutinib | |
| IL251584B (en) | Dihydropyrrolopyridines ror–gamma inhibitors | |
| SG11201609265RA (en) | Characterizing states of subject | |
| IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| SI3154526T1 (sl) | Trdne oblike sofosbuvira | |
| IL265628A (en) | Solid state forms of valbenazine | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| PT3113773T (pt) | Formas cristalinas do grapiprant | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| ZA201608686B (en) | Interseparation of metals | |
| IL246569A0 (en) | Solid forms of tenofovir | |
| IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
| IL254666A0 (en) | Crystalline forms of Aldecalcitol | |
| IL249332A0 (en) | Crystalline forms of sofosbuvir | |
| GB201418230D0 (en) | Construction of surfaces | |
| GB201418773D0 (en) | Mechanism of action | |
| GB201405155D0 (en) | Theory of entertainment | |
| GB201402924D0 (en) | The theory of instantransmission | |
| GB201413138D0 (en) | Assessment of structures | |
| GB201413139D0 (en) | Assessment of structures | |
| TWM489230U (en) | Improved structure of pin set | |
| GB201405157D0 (en) | Theory of international law | |
| HUP1400294A2 (hu) | Clopidogrel új alkalmazása | |
| GB201412359D0 (en) | Composition of objects |